Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: Impact on virological response to efavirenz-based therapy

AIDS

Volumn 15, Issue 9, 2001, Pages 1125-1132

  Shulman, Nancy ^a   Zolopa, Andrew R ^a   Passaro, Doug ^a   Shafer, Robert W ^a   Huang, Wei ^a   Katzenstein, David ^a   Israelski, Dennis M ^a   Hellmann, Nick ^a   Petropoulos, Chris ^a   Whitcomb, Jeannette ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; Efavirenz; HIV; Non nucleoside reverse transcriptase inhibitors

Indexed keywords

DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTANT; VIRUS RESISTANCE;

ANTI-HIV AGENTS; COHORT STUDIES; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS; MUTAGENESIS; NUCLEOSIDES; OXAZINES; PHENOTYPE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035876456     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200106150-00007     Document Type: Article

References (27)

1. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
2. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
3. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors
4. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture
5. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine
6. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
7. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase
8. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy
9. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. Italy, The Netherlands, Canada and Australia Study
10. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team
11. The Atlantic Study: A randomized open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48-week data
12. ACTG 364: Virologic efficacy of nelfinavir (NFV) and/or efavirenz (EFZ) in combination with new nucleoside analogs in nucleoside experienced subjects (subj)
13. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
14. Reduced susceptibility to NRTI is associated with NNRTI hypersensitivity in virus from HIV-1 infected patients
15. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: Clinical and genotypic predictors of virologic response
16. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
17. Mutations in retroviral genes associated with drug resistance
18. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
19. Validation of the performance characteristics of a novel, rapid phenotypic drug susceptibility assay, PhenoSense HIV
20. Non-nucleoside reverse transcriptase inhibitor viral hypersensitivity is common and improves short term virological response
21. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
22. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel
23. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy
24. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naive patients (study DMP 266-006)
25. Virological response to nelfinavir, efavirenz, or both in patients with > 4 years of previous nucleoside RT inhibitors in ACTG 364
26. Selection of zidovudine resistance mutations by stavudine or stavudine-based regimens and relationship to subsequent virological response in ACTG 370
27. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir or both in HIV-infected adults with virologic failure on indinavir: Aids Clinical Trials Group (ACTG) Study 359